SCHEMBL5550237

SCHEMBL5550237

Cn1c(=O)c(=O)[nH]c2cc(F)ccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 1/20 0.56
GRIA2 P42262 1/20 0.56
GRIA3 P42263 1/20 0.56
GRIA4 P48058 1/20 0.56
KDM4E B2RXH2 2/20 0.52
DAO P14920 5/20 0.51
DDO Q99489 1/20 0.44
FEN1 P39748 2/20 0.41
PARP1 P09874 1/20 0.41
PARG Q86W56 2/20 0.40
OPRM1 P35372 1/20 0.40
OPRL1 P41146 1/20 0.40
GABRP O00591 1/20 0.39
GABRD O14764 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30770202 0.86 GRIA1 (0.56) GRIA1GRIA2GRIA3GRIA4KDM4E
SCHEMBL194166 0.82 DAO (0.64) KDM4EDAOFEN1GABRPGABRD
SCHEMBL31192592 0.82 DAO (0.64) KDM4EDAOFEN1GABRPGABRD
SCHEMBL7359339 0.81 GRIA1 (0.57) GRIA1GRIA2GRIA3GRIA4KDM4E
SCHEMBL8138622 0.79 DAO (0.70) KDM4EDAODDOFEN1PARP1
SCHEMBL31439104 0.79 GRIA1 (0.60) GRIA1GRIA2GRIA3GRIA4KDM4E
SCHEMBL8403660 0.79 GRIA1 (0.60) GRIA1GRIA2GRIA3GRIA4KDM4E
SCHEMBL9398023 0.79 GRIA1 (0.65) GRIA1GRIA2GRIA3GRIA4DAO
SCHEMBL7968233 0.79 GRIA1 (0.56) GRIA1GRIA2GRIA3GRIA4PARG
SCHEMBL9395706 0.79 GRIA1 (0.51) GRIA1GRIA2GRIA3GRIA4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1711184-B1 (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA NV (BE) 2007-07-18 EP disclosed
EP-1711184-B1 (3-OXO-3,4-DIHYDRO-QUINOXALIN-2-YL-AMINO)-BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS GLYCOGEN PHOSPHORYLASE INHIBITORS FOR THE TREATMENT OF DIABETES AND OBESITY JANSSEN PHARMACEUTICA NV (BE) 2007-07-18 EP disclosed
US-20050148586-A1 Quinoxalinones JANSSEN PHARMACEUTICA, N.V. (BE) 2005-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148586-A1 Quinoxalinones SLC5A2, GPR119, GLS2 GRIA1 2287/4885GRIA2 2073/4885GRIA3 1427/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.